ALPMY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 01:17):

Stats
आज की मात्रा	201 811
औसत मात्रा	327 655
बाजार मूल्य	18.05B
EPS	$0 ( 2024-04-25 )
अगली कमाई की तारीख	( $0 ) 2024-08-06
Last Dividend	$0.220 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	503.20
ATR14	$0.0140 (0.14%)

मात्रा सहसंबंध

लंबा: -0.06 (neutral)

छोटा: -0.27 (neutral)

Signal:(39.588) Neutral

Astellas Pharma Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Astellas Pharma Inc. सहसंबंध - मुद्रा/वस्त्र

-0.34
( neutral )

-0.17
( neutral )

0.00
( neutral )

-0.35
( neutral )

0.51
( weak )

0.29
( neutral )

Astellas Pharma Inc. वित्तीय

Annual	2024
राजस्व:	$1 603.67B
सकल लाभ:	$1 212.37B (75.60 %)
EPS:	$9.50

FY	2024
राजस्व:	$1 603.67B
सकल लाभ:	$1 212.37B (75.60 %)
EPS:	$9.50

FY	2023
राजस्व:	$1 518.62B
सकल लाभ:	$1 191.83B (78.48 %)
EPS:	$54.24

FY	2022
राजस्व:	$1 296.16B
सकल लाभ:	$1 014.87B (78.30 %)
EPS:	$67.08

Financial Reports:

No articles found.

Astellas Pharma Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Astellas Pharma Inc. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.96 - good (89.56%) | Divividend Growth Potential Score: 5.72 - Stable (14.49%)

Information

First Dividend	$0.192	2021-03-29
Last Dividend	$0.220	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.412	--
Avg. Dividend % Per Year	0.00%	--
Score	3.22	--
Div. Sustainability Score	8.96
Div.Growth Potential Score	5.72
Div. Directional Score	7.34	--

Next Divdend (Est)
(2024-06-21)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.22

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
YITYY	Ex Dividend Junior	2023-10-02	Annually	0.00%
LZRFY	Ex Dividend Knight	2023-07-03	Bi-Monthly	0.00%
CHDRY	Ex Dividend Knight	2023-12-04	Semi-Annually	0.00%
SOTGY	Ex Dividend Junior	2023-05-26	Annually	0.00%
GMVHY	Ex Dividend Junior	2023-08-18	Semi-Annually	0.00%
ADRNY	Ex Dividend Knight	2023-08-11	Annually	0.00%
NHMD	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
CNPWP	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
TINLF	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
HSNGY	Ex Dividend Knight	2023-08-11	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00805	1.500	9.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00362	1.200	9.88	10.00	[0 - 0.3]
returnOnEquityTTM	0.00817	1.500	-1.020	-1.530	[0.1 - 1]
payoutRatioTTM	9.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	0.929	0.800	-0.354	-0.283	[1 - 3]
quickRatioTTM	0.687	0.800	-0.663	-0.530	[0.8 - 2.5]
cashRatioTTM	0.261	1.500	9.66	10.00	[0.2 - 2]
debtRatioTTM	0.258	-1.500	5.70	-8.56	[0 - 0.6]
interestCoverageTTM	14.83	1.000	5.62	5.62	[3 - 30]
operatingCashFlowPerShareTTM	101.14	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	55.12	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.576	-1.500	7.69	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.756	1.000	0.733	0.733	[0.2 - 0.8]
operatingProfitMarginTTM	0.111	1.000	9.78	9.78	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.197	1.000	-0.0162	-0.0162	[0.2 - 2]
assetTurnoverTTM	0.449	0.800	-0.338	-0.271	[0.5 - 2]
Total Score				8.96

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	214.74	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.00817	2.50	-0.656	-1.530	[0.1 - 1.5]
freeCashFlowPerShareTTM	55.12	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0237	1.500	9.41	0	[0 - 0.4]
operatingCashFlowPerShareTTM	101.14	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	9.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.421	1.500	-0.525	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.113	1.000	9.67	0	[0.1 - 0.5]
Total Score				5.72

Astellas Pharma Inc.

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.